AVBP vs AXSM Stock Comparison
AXSM currently leads AVBP in this stock comparison, with AIQ scores of 47 vs 35. The clearest difference is risk resilience.
What is the main difference between AVBP and AXSM?
AXSM leads the current stock comparison as Axsome Therapeutics, Inc., with the clearest separation coming from risk resilience and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
ArriVent BioPharma, Inc. vs Axsome Therapeutics, Inc.
AXSM leads
AXSM leads by 12 AIQ points, primarily on Risk Resilience and Quality. Wall Street currently favors AVBP on target upside.
Competitive: 3 of 5 evidence groups support AXSM, and its current signal state is conflicted.
ArriVent BioPharma, Inc.
Axsome Therapeutics, Inc.
The Algovestiq AIQ Score currently favors AXSM over AVBP, 47 versus 35 as of Nov 15, 2026. AXSM's advantage is driven primarily by stronger risk resilience and quality. AXSM also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors AVBP. 3 of 5 covered evidence groups favor AXSM today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. AXSM lead: Stable — the AIQ differential has held near 12 points over 30 sessions.
Compare ArriVent BioPharma, Inc. and Axsome Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare AVBP and AXSM against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience32 vs 57AXSM +25
- Quality51 vs 57AXSM +6
- Momentum23 vs 24Even
3 of 5 evidence groups favor AXSM. AXSM’s edge is concentrated in risk resilience and quality.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +7
No signal started or stopped since the prior session; its 4 active signals are unchanged.
Largest factor move: Quality +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 4 active signals are unchanged.
AXSM's lead narrowed by 3 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — AVBP and AXSM both carry a full feed there.
The central trade-off
AXSM (Axsome Therapeutics, Inc.): the stronger current systematic profile, led by risk resilience and quality.
AVBP (ArriVent BioPharma, Inc.): the counter-case, on analyst expectations — but at materially higher volatility, 132.6% against 53.2%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
AXSMAXSM on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
AXSMAXSM on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
EvenThe two are level on Momentum.
Lower downside
AXSMAXSM on Risk Resilience, by 25 points.
Analyst upside
AVBPAVBP on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors AXSM, analyst targets favor AVBP. That disagreement is the most useful thing on this page.
| Measure | AVBP | AXSM | Note |
|---|---|---|---|
| Implied upside to target | +96.6% | +83.6% | AVBP has more room |
| Target dispersion | +46.9% | +21.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 11 | 22 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor AXSM. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | AXSM | 35 vs 47 |
| Fundamentals | Even | EPS growth 22.9% vs 74.7%; TTM ROE -10.2% vs -12.2%; gross margin 100% vs 93.2%; operating margin -36.2% vs -17.7% |
| Valuation | Not covered | Not covered |
| Technicals | AXSM | Price vs 50-day -39.1% vs -17.4%; vs 200-day -50.9% vs -28.1% |
| Risk Resilience | AXSM | Risk Resilience 32 vs 57 |
| Analyst expectations | AVBP | Target upside 96.6% vs 83.6% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AVBP and AXSM and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 12 points. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on AXSM.
How the comparison changed
120 daily snapshots · May 27 – Nov 13AXSM lead: Stable — the AIQ differential has held near 12 points over 30 sessions.
- Today
- AXSM +12
- 35 vs 47
- 7 sessions ago
- AXSM +7
- 40 vs 47
- 30 sessions ago
- AXSM +10
- 41 vs 51
- 90 sessions ago
- AVBP +6
- 67 vs 61
The lead changed hands 2 times in this window, most recently on Oct 6 when AXSM moved ahead of AVBP.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
AVBP and AXSM carry the same 4 signals, so the signals do not separate them: Death Cross Active, ATR Expansion - Breakout Mode, Downtrend Structure Active, MACD Histogram Expanding Bullish.
AXSM leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is down while the AIQ Score moved up 3 points over the same session — price and model disagree (price -0.46%, AIQ +3 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.86%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1AVBP closes the Risk Resilience gap — currently 25 points behind, the largest single contributor to AXSM's edge.
- 2AVBP's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3AXSM's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | AVBP | AXSM |
|---|---|---|
| Revenue growth (YoY) | 0% | 18.9% |
| EPS growth (YoY) | 22.9% | 74.7% |
| Gross margin | 100% | 93.2% |
| Operating margin | -36.2% | -17.7% |
| Return on equity (TTM) | -10.2% | -12.2% |
| Debt to equity | 0 | 2.07 |
Performance
AXSM leads 6 of 6 windows| Metric | AVBP | AXSM |
|---|---|---|
| 1 week (5 sessions) | -4.6% | 7% |
| 1 month (20 sessions) | -21.9% | -9.8% |
| 3 months (63 sessions) | -55.2% | -34.5% |
| 6 months (126 sessions) | -53.3% | -37.8% |
| Year to date | -35.3% | -22.4% |
| 1 year (252 sessions) | -35.6% | 0.6% |
Technicals
AXSM has the stronger structure| Metric | AVBP | AXSM |
|---|---|---|
| RSI (14) | 34.1 | 40.8 |
| ADX (14) | 31.9 | 37.2 |
| Price vs 50-day | -39.1% | -17.4% |
| Price vs 200-day | -50.9% | -28.1% |
| Volatility (1M, annualized) | 132.6% | 53.2% |
Risk
AXSM is the more resilient| Metric | AVBP | AXSM |
|---|---|---|
| Beta | 1.14 | 0.66 |
| Sharpe ratio | -0.08 | 0.2 |
| Sortino ratio | -0.1 | 0.34 |
| Max drawdown | -64.8% | -49.1% |
| Current drawdown | -62.6% | -44.5% |
| Annualized volatility | 81.5% | 45.8% |
| Value at risk (95%) | -5.3% | -4.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, AVBP or AXSM?
On the Algovestiq AIQ Score, AXSM is the stronger of the two as of Nov 15, 2026, scoring 47 against AVBP's 35. The edge comes from risk resilience and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is AVBP or AXSM the better buy right now?
AXSM carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor AXSM over AVBP?
The composite weights Quality, Value, Momentum and Risk Resilience. AXSM leads Risk Resilience by 25 points; AXSM leads Quality by 6 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, AVBP or AXSM?
Analyst price targets imply +96.6% upside for AVBP and +83.6% for AXSM, so the Street currently favors AVBP. That points the opposite way to the AIQ Score, which favors AXSM. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, AVBP or AXSM?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, AVBP or AXSM?
AXSM on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, AVBP or AXSM?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, AVBP or AXSM?
AXSM is the more resilient of the two, so the other name carries the higher downside risk. AXSM on Risk Resilience, by 25 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is AVBP more profitable than AXSM?
The profitability evidence is mixed: gross margin 100% vs 93.2%; operating margin -36.2% vs -17.7%; ttm roe -10.2% vs -12.2%. AVBP leads on two measures and AXSM on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is AXSM's lead over AVBP getting stronger or weaker?
AXSM lead: Stable — the AIQ differential has held near 12 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-10-06, when AXSM moved ahead of AVBP.
What would change the AVBP vs AXSM verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: AVBP closes the Risk Resilience gap — currently 25 points behind, the largest single contributor to AXSM's edge; AVBP's Death Cross Active resolves — a bearish trend rule currently active against it; AXSM's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about AVBP and AXSM?
AVBP: 1 bullish / 2 bearish / 1 neutral, conflicted. AXSM: 1 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AVBP is Death Cross Active (bearish, long horizon). On AXSM it is Death Cross Active (bearish, long horizon).
Compare AVBP and AXSM with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.